P/CLOUDY
A Health Department panel has delayed approval of Shionogi’s COVID-19 antiviral pill, concluding it wants more knowledge before making a judgment about its effectiveness.
The delay is a blow to one of Japan’s largest drug brands and raises questions about the expedited drug approval procedure in case of emergency.
This may be due to a conflict with your security or ad-blocking software.
Upload japantimes. co. jp and piano. io to your list of sites.
If this isn’t enough or if you can’t load the domain names on your whitelist, stop on this help page.
We humbly for the inconvenience.
In an age of misinformation and too much information, quality journalism is more important than ever. By subscribing, you can help us tell the story well.
Your subscription plan allows you to comment. To be more informed, see our frequently asked questions
The Japan Times LTD. All rights reserved.